LOS ANGELES, March 30, 2016 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today
announced financial results for 2015.
Andrew Gengos, ImmunoCellular
Chief Executive Officer, commented: "We made important progress in
advancing the company in 2015. In particular, we designed and
began executing what we believe is the best possible phase 3
registration trial for ICT-107 in patients with newly diagnosed
glioblastoma. We took full advantage of about five years of
placebo-controlled survival data and immune monitoring results from
the phase 2 trial, conversations with key opinion leaders in the
field of glioblastoma and discussions with major regulatory bodies
in designing this trial. The process of bringing clinical sites
online and screening patients in the US is accelerating, and we
anticipate that all sites in the US, Canada and Europe will be activated by the end of 2016.
In addition, our research relationships and collaborations with
prestigious academic institutions, including the University of Texas MD Anderson Cancer Center,
Stanford University and the
University of Maryland, are progressing
well, and represent value-enhancing opportunities for our Company.
We are proud of the progress we made in 2015, and are looking
forward to delivering another year of growth and achievement in
2016."
For the year ended December 31,
2015, ImmunoCellular incurred a net loss of $12.8 million, or $0.15 per basic and diluted share, compared to a
net loss of $9.4 million, or
$0.16 per basic and diluted share,
for the year ended December 31,
2014. During 2015 the Company incurred $10.9 million of research and development
expenses compared to $6.0 million in
2014. The $4.9 million increase
primarily reflects the additional expenses associated with the
phase 3 trial of ICT-107. General and administrative expenses
increased in 2015 to $4.6 million
from $3.9 million in 2014, primarily
due to additional professional fees and payroll-related expenses.
During 2015, the Company recorded a credit to other income of
$2.9 million to reflect a write-down
in the Company's warrant liability compared to a credit to other
income of $530,000 in 2014. For the
quarter ended December 31, 2015, the
Company recorded a net loss of $4.8
million, or $0.05 per basic
and diluted share, compared to $2.1
million, or $0.03 per basic
and diluted share, during the same period in 2014. The
increase in the net loss between periods reflects the additional
costs of the phase 3 trial of ICT-107.
The Company also reported that cash used in operations in 2015
was $19.0 million compared to
$9.9 million in 2014. In
addition to the incremental expenses associated with starting the
phase 3 trial of ICT-107, the Company also purchased $2.2 million in supplies and made additional
vendor deposits of $3.7 million
related to the trial. These items will benefit future periods and
are reflected on the Company's balance sheet at December 31, 2015.
During 2015, the Company raised $14.6
million net of offering costs from the issuance of
26,650,000 shares of common stock and warrants to purchase
18,655,000 shares. The warrants have a term of five years and an
exercise price of $0.66. During the
third quarter of 2015, the Company was awarded $19.9 million from the California Institute of
Regenerative Medicine (CIRM) that the Company will be entitled to
receive as patients are enrolled in the phase 3 trial of ICT-107,
and during the fourth quarter of 2015, the Company received
$4.0 million in its first award
payment from CIRM. The next award payment is anticipated to be
$3.0 million when the next enrollment
milestone is achieved. As of December
31, 2015, the Company had $22.6
million in cash.
The Company has agreed in principle with the staff of the SEC on
a proposed settlement framework to an investigation related
principally to its former Chief Executive Officer involving conduct
between November 2011 and August
2012. If the settlement is approved, the Company would consent
to the entry of an administrative order requiring that we cease and
desist from any future violations of Sections 5, 17(a), and 17(b)
of the Securities Act of 1933, as amended, and Section 10(b) of the
Securities Exchange Act of 1934, as amended, without admitting or
denying any allegations. The proposed settlement also involves the
adoption of certain corporate governance amendments to the
Company's policies and practices, in particular as it relates to
the retention of investor relations and public relations
firms. The proposed settlement is contingent upon execution of
a formal offer of settlement and approval by the Commissioners of
the SEC, neither of which can be assured. Based upon the
settlement framework with the staff of the SEC, the Company
has not accrued and does not currently expect to accrue a liability
related to this matter. However, any final settlement must be
approved by the Commissioners. If the Commissioners do not
approve the settlement, the Company may need to enter into further
discussions with the SEC to resolve the investigated matters
on different terms and conditions. As a result, there can be no
assurance as to the final terms of any settlement including its
financial impact or any future adjustment to the financial
statements.
Conference Call and Webcast Today
ImmunoCellular plans to hold a conference call and webcast today
at 5:00 pm ET to discuss the 2015
financial results and business update. The call will be hosted by
Andrew Gengos, President and
CEO.
LIVE CALL:
|
(877) 853-5636
(toll-free); international dial-in: (631) 291-4544; conference code
81163640.
|
|
|
WEBCAST:
|
Interested parties
who wish to listen to the webcast should visit the Investor
Relations section of ImmunoCellular's website at www.imuc.com,
under the Events and Presentations tab. A replay of the webcast
will be available one hour after the conclusion of the
event.
|
The conference call will contain forward-looking statements. The
information provided on the teleconference is accurate only at the
time of the conference call, and ImmunoCellular will take no
responsibility for providing updated information except as required
by law.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. The phase 3 registrational trial of lead product
candidate, ICT-107, a dendritic cell-based immunotherapy targeting
multiple tumor-associated antigens on glioblastoma stem cells, is
open for patient screening. ImmunoCellular's pipeline also
includes: ICT-121, a dendritic cell immunotherapy targeting the
CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a
dendritic cell immunotherapy targeting antigens on ovarian cancer
stem cells; and the Stem-to-T-cell research program which engineers
the patient's hematopoietic stem cells to generate antigen-specific
cancer-killing T cells. To learn more about ImmunoCellular, please
visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements,
including statements regarding the development and
commercialization of ICT-107, initiation of a phase 3 study of
ICT-107, whether or not the SEC will approve as final the
settlement terms agreed upon with the enforcement division, the
advancement of the ICT-121 phase 1 trial, the development of our
preclinical Stem-to-T-cell program and our ability to achieve our
other clinical, operational and financial goals. These statements
are based on ImmunoCellular's current expectations and involve
significant risks and uncertainties, including those described
under the heading "Risk Factors" in ImmunoCellular's most recently
filed quarterly report on Form 10-Q and annual report on Form 10-K.
Except as required by law, ImmunoCellular undertakes no obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Consolidated Balance
Sheets
|
|
|
|
|
|
|
|
|
12/31/2015
|
12/31/2014
|
|
Cash
|
$ 22,604,481
|
$ 23,222,296
|
|
Other current
assets
|
1,956,057
|
1,219,873
|
|
Non current
assets
|
5,521,836
|
736,392
|
|
Total
assets
|
$ 30,082,374
|
$ 25,178,561
|
|
|
|
|
|
Current
liabilities
|
$ 2,269,398
|
$
1,289,199
|
|
Warrant
liability
|
1,958,775
|
597,719
|
|
CIRM
liability
|
4,133,905
|
-
|
|
Total
liabilities
|
8,362,078
|
1,886,918
|
|
Shareholders'
equity
|
21,720,296
|
23,291,643
|
|
|
$ 30,082,374
|
$ 25,178,561
|
|
|
|
|
|
|
|
|
|
Consolidated
Statements of Operations
|
|
|
|
|
|
|
|
|
Year
|
Year
|
Year
|
|
ended
|
ended
|
ended
|
|
2015
|
2014
|
2013
|
Revenue
|
$
-
|
$
-
|
$
-
|
Research and
development
|
10,896,591
|
5,969,182
|
5,339,716
|
General and
administrative
|
4,616,500
|
3,889,359
|
4,120,603
|
Loss before other
expenses
|
(15,513,091)
|
(9,858,541)
|
(9,460,319)
|
Interest
income
|
19,863
|
13,917
|
17,345
|
Interest
expense
|
(133,905)
|
-
|
-
|
Financing
expense
|
(88,939)
|
(62,683)
|
-
|
Change in fair value
of warrant liability
|
2,925,258
|
529,774
|
642,411
|
Net loss
|
$ (12,790,814)
|
$ (9,377,533)
|
$ (8,800,563)
|
|
|
|
|
Net loss per share,
basic and diluted:
|
$
(0.15)
|
$
(0.16)
|
$
(0.16)
|
Contact:
ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com
Logo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-announces-2015-financial-results-300243609.html
SOURCE ImmunoCellular Therapeutics, Ltd.